美國男性脫髮症市場規模、佔有率、趨勢分析報告：按治療、銷售管道、性別、最終用途、細分市場預測，2025-2030 年

美國男性脫髮症市場的趨勢：

預計到 2024 年，美國男性脫髮症市場規模將達到 9.791 億美元，2025 年至 2030 年的複合年成長率為 6.6%。

男性脫髮症(AGA) 的盛行率不斷上升，推動著市場成長。作為最常見的脫髮症，男性脫髮症影響著相當一部分人口，其中老齡化和遺傳因素也起著一定作用。隨著脫髮預防意識的增強，越來越多的人開始尋求治療，從而擴大了市場。根據美國國家醫學圖書館 2023 年 7 月發布的數據，美國約有 5,000 萬名男性和 3,000 萬名女性患有男性脫髮症(AGA)。

另一個因素是治療方案的進步。市場正在見證各種創新治療方法的推出，例如外用溶液、口服藥物以及富血小板血漿 (PRP) 療法和植髮手術等微創手術。製藥公司也加大研發投入，以開發更有效、更方便的治療方法方法，從而吸引更廣泛的消費者群體。

新藥核准和市場供應的不斷擴大將進一步推動市場成長。 2025年6月，Pelagie Pharmaceuticals宣布了PP405的2a期臨床試驗的正面結果。 PP405是一種透過重新運作暫停狀態毛囊幹細胞來治療掉髮的局部治療藥物。這項進展使Pelagie成為男性脫髮症再生醫學領域的領導者。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國男性脫髮症市場變數、趨勢與範圍

• 市場展望
  • 母市場展望
  • 相關/支持市場展望
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
• 美國男性脫髮症市場分析工具
  • 產業分析-波特五力分析
  • PESTEL分析
• 美國男性脫髮症市場：通路分析

第4章美國男性脫髮症市場：治療評估與趨勢分析

• 治療細分儀表板
• 美國男性脫髮症市場：治療差異分析
• 美國男性脫髮症市場規模及趨勢分析（依治療方法，2018-2030）
• 製藥
• 裝置

第5章美國男性脫髮症市場：最終用途估計與趨勢分析

• 最終用途細分儀表板
• 美國男性脫髮症市場：最終用途趨勢分析
• 2018-2030年美國男性脫髮症市場規模及趨勢分析（依最終用途）
• 居家照護環境
• 皮膚科診所

第6章美國男性脫髮症市場：銷售管道評估與趨勢分析

• 銷售管道細分儀表板
• 美國男性脫髮症市場：銷售管道變化分析
• 美國男性脫髮症市場規模及銷售管道趨勢分析（2018-2030）
• 處方箋
• 非處方藥

第7章美國男性脫髮症市場：性別估計與趨勢分析

• 男性
• 女士

第8章 競爭態勢

• 主要市場參與企業的近期趨勢和影響分析
• 公司/競爭對手分類
• 供應商格局
  • Key company heat map analysis, 2024
• 公司簡介
  • Johnson &Johnson Services, Inc.
  • Cipla
  • Sun Pharmaceutical Industries Ltd.
  • Merck &Co., Inc
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Hairmax International LLC
  • Freedom Laser Therapy, Inc.（iRESTORE Hair Growth System）
  • Curallux, LLC
  • Apira Science, Inc.（iGROW Laser）
  • Theradome Inc.

U.S. Androgenetic Alopecia Market Trends:

The U.S. androgenetic alopecia market was valued at USD 979.1 million in 2024 and is expected to grow at a CAGR of 6.6% from 2025 to 2030. The increasing incidence of Androgenic Alopecia (AGA) is driving market growth. Androgenetic alopecia, the most common form of hair loss, affects a significant portion of the population, with aging and genetic factors playing a role. As awareness about hair loss solutions rises, more individuals seek treatments, expanding the market. According to data published by the National Library of Medicine in July 2023, approximately 50 million men and 30 million women in the U.S. were affected by androgenetic alopecia (AGA).

Another factor is the advancement in treatment options. The market has witnessed the introduction of innovative therapies, such as topical solutions, oral medications, and minimally invasive procedures such as platelet-rich plasma (PRP) therapy and hair transplant surgeries. Pharmaceutical companies also invest in research and development to create more effective and convenient treatments, attracting a broader consumer base.

The approval of new drugs and the expansion of over-the-counter products further propel market growth. In June 2025, Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405, a topical treatment targeting hair loss by reactivating dormant hair follicle stem cells. This advancement positions Pelage as a leader in regenerative medicine for androgenetic alopecia.

U.S. Androgenetic Alopecia Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. androgenetic alopecia market report based on treatment, end use, sales channel, and gender:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceuticals
• Devices
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Homecare Settings
• Dermatology Clinics
• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Prescriptions
• OTC
• Gender Outlook (Revenue, USD Million, 2018 - 2030)
• Male
• Female

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Sales Channel
  • 1.2.4. Gender
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Sales Channel Outlook
  • 2.2.4. Gender Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Androgenetic Alopecia Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Androgenetic Alopecia Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape
• 3.4. U.S. Androgenetic Alopecia Market: Pipeline Analysis

Chapter 4. U.S. Androgenetic Alopecia Market: Treatment Estimates & Trend Analysis

• 4.1. Treatment Segment Dashboard
• 4.2. U.S. Androgenetic Alopecia Market: Treatment Movement Analysis
• 4.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Pharmaceuticals
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Devices
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Androgenetic Alopecia Market: End Use Estimates & Trend Analysis

• 5.1. End Use Segment Dashboard
• 5.2. U.S. Androgenetic Alopecia Market: End Use Movement Analysis
• 5.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Homecare Settings
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Dermatology Clinics
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Androgenetic Alopecia Market: Sales Channel Estimates & Trend Analysis

• 6.1. Sales Channel Segment Dashboard
• 6.2. U.S. Androgenetic Alopecia Market: Sales Channel Movement Analysis
• 6.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 6.4. Prescriptions
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD million)
• 6.5. OTC
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis

• 7.1. Male
  • 7.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.2. Female
  • 7.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Johnson & Johnson Services, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Cipla
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Sun Pharmaceutical Industries Ltd.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Merck & Co., Inc
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Dr. Reddy's Laboratories Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Aurobindo Pharma Limited
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Hairmax International LLC
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Curallux, LLC
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Apira Science, Inc. (iGROW Laser)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Theradome Inc.
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
• Table 3 U.S. androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
• Table 4 U.S. androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
• Table 5 U.S. androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. androgenetic alopecia market: market outlook
• Fig. 10 U.S. androgenetic alopecia competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. androgenetic alopecia market driver impact
• Fig. 16 U.S. androgenetic alopecia market restraint impact
• Fig. 17 U.S. androgenetic alopecia market strategic initiatives analysis
• Fig. 18 U.S. androgenetic alopecia market: Treatment movement analysis
• Fig. 19 U.S. androgenetic alopecia market: Treatment outlook and key takeaways
• Fig. 20 Pharmaceuticals market estimates and forecast, 2018 - 2030
• Fig. 21 Devices market estimates and forecast, 2018 - 2030
• Fig. 22 U.S. androgenetic alopecia market: End Use movement analysis
• Fig. 23 U.S. androgenetic alopecia market: End Use outlook and key takeaways
• Fig. 24 Homecare settings market estimates and forecasts, 2018 - 2030
• Fig. 25 Dermatology clinics market estimates and forecasts, 2018 - 2030
• Fig. 26 U.S. androgenetic alopecia market: Sales channel movement analysis
• Fig. 27 U.S. androgenetic alopecia market: Sales channel outlook and key takeaways
• Fig. 28 Prescriptions market estimates and forecasts, 2018 - 2030
• Fig. 29 OTC market estimates and forecasts, 2018 - 2030
• Fig. 30 U.S. androgenetic alopecia market: Gender movement analysis
• Fig. 31 U.S. androgenetic alopecia market: Gender outlook and key takeaways
• Fig. 32 Male market estimates and forecasts, 2018 - 2030
• Fig. 33 Female market estimates and forecasts, 2018 - 2030